All J&J articles – Page 2
-
-
BusinessChemical and pharma bosses quit US manufacturing council
President Trump disbands the group after multiple advisers resign in protest against his stance on racism
-
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
-
BusinessJ&J fights talc cancer claims
Firm has lost several court cases linking talc to ovarian cancer, but vows to appeal
-
BusinessJ&J to close Scottish medical device plant
Up to 400 positions affected as Ethicon subsidiary leaves Livingston
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessJ&J to buy Abbott Medical Optics
Deal adds laser surgery and cataract lens replacements to J&J’s eyecare business
-
BusinessJ&J to buy Vogue for haircare range
$3.3bn deal expands Johnson & Johnson’s consumer products segment
-
Business
J&J to cut 3000 jobs in medical devices unit
Cost-saving cuts will help ‘accelerate the pace of innovation’, company claims
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
-
Business
Consumer products firms fined for French price fixing
€950m fines for ‘friends clubs’ that pushed up prices for home and personal care products
-
Business
J&J to buy antiviral specialist Alios
$1.75 billion deal brings Phase II compounds for hepatitis C and respiratory syncytial virus
-
BusinessEMA wrangles restrain trial data progress
Attempts to balance industry and research interests on transparency draw suggestions of improper collusion
-
Business
$1.2bn J&J deceptive marketing fine overturned
Supreme court reverses decision to fine firm over Risperdal promotion
-
BusinessJ&J puts trial data in independent hands
Yale University’s YODA seeks to help pharma avoid the dark side by acting as gatekeeper for patient records
-
FeatureThe hunt for innovation
Big pharma companies are embracing a more open and collaborative approach. Nuala Moran discovers who’s working with whom
-
-
BusinessNew wave of hepatitis C drugs hits US shore
J&J’s once-daily drug approved by FDA, but rivals are hot on its heels
- Previous Page
- Page1
- Page2
- Page3
- Next Page